Join to View Full Profile
1008 Minnequa AvePueblo, CO 81004
Phone+1 800-228-4039
Dr. Tandon is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Ankita Tandon, DO is an Oncologist based in Colorado. She completed her Internal Medicine residency in 2021 at University of South Florida Morsani, after graduating from the University of New England College of Osteopathic Medicine in 2018. She has published several research studies in noted medical journals like the Journal for Immunotherapy of Cancer, Transplantation and Cellular Therapy, Clinical Genitourinary Cancer, JCO Precision Oncology, and In Vivo. Her publications touch on a range of oncology-related topics and are frequently cited by other researchers in the field.
Education & Training
University of South Florida MorsaniResidency, Internal Medicine, 2018 - 2021
University of New England College of Osteopathic MedicineClass of 2018
Certifications & Licensure
CO State License 2024 - 2027
IL State License 2021 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study.Amin H Nassar, Sarah Abou Alaiwi, Talal El Zarif, Ryan Denu, Walid Macaron
Journal for Immunotherapy of Cancer. 2025-03-03 - 9 citationsOutcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection.Zeynep Eroglu, Kristy K Broman, John F Thompson, Amanda Nijhuis, Tina J Hieken
Journal for Immunotherapy of Cancer. 2022-08-01 - 3 citationsOutcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation.Abu-Sayeef Mirza, Ankita Tandon, Dakota Jenneman, Shu Cao, Thomas Brimer
Transplantation and Cellular Therapy. 2022-04-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
